SpectruMedix, Capital Genomix Enter Into Distribution Agreement

SpectruMedix and Capital Genomix have announced that they have entered into a worldwide, exclusive distribution agreement to market and sell GeneSystem320 (GS320) for capillary electrophoresis-based applications. Jill Ray, vice president of R&D at Capital Genomix, describes the platform as a "method for differential gene expression analysis that exceeds the capabilities of other currently available products." GS320 is the first simple, unbiased and complete gene expression analysis solution. The GS320 technology is a rapid method to detect and identify all transcripts present at very low levels.

PharmaLive (http://www.pharmalive.com/News/index.cfm?articleid=236241&categoryid=15)